poster

Leveraging the semantic web and natural language processing to enhance drug-mechanism knowledge in drug product labels

Authors:

Mike ConwayAuthors Info & Claims

IHI '10: Proceedings of the 1st ACM International Health Informatics Symposium

Pages 492 - 496

https://doi.org/10.1145/1882992.1883070

Published: 11 November 2010 Publication History

Abstract

Multiple studies indicate that drug-drug interactions are a significant source of preventable adverse drug events. Factors contributing to the occurrence of preventable ADEs resulting from DDIs include a lack of knowledge of the patient's concurrent medications and inaccurate or inadequate knowledge of interactions by health care providers. FDA-approved drug product labeling is a major source of information intended to help clinicians prescribe drugs in a safe and effective manner. Unfortunately, drug product labeling has been identified as often lagging behind emerging drug knowledge; especially when it has been several years since a drug has been released to the market. In this paper we report on a novel approach that explores employing Semantic Web technology and natural language processing to identify drug mechanism information that may update or expand upon statements present in product labeling.

References

[1]

Amgen. SENSIPAR (cinacalcet hydrochloride) tablet, coated. FDA-approved drug product labeling, 122008. Last accessed on DailyMed 06/29/2009.

[2]

Apotex. fluconazole (fluconazole) solution. FDA-approved drug product labeling, 01 2007. Lastaccessed on DailyMed 05/22/2010.

[3]

R. Boyce, C. Collins, J. Horn, and I. Kalet. Modelingdrug mechanism knowledge using evidence and truth maintenance. IEEE Transactions on Information Technology in Biomedicine, 11(4):386--397, 2007.

Digital Library

[4]

R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part I: A drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform, 42(6):979--989, 2009.

Digital Library

[5]

R. Boyce, C. Collins, J. Horn, and I. Kalet. Computing with evidence part II: An evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform, 42(6):990--1003, 2009.

Digital Library

[6]

W. W. Chapman, W. Bridewell, P. Hanbury, G. F.Cooper, and B. G. Buchanan. A simple algorithm for identifying negated findings and diseases in discharge summaries. J Biomed Inform, 34(5):301--10, Oct 2001.

[7]

Y.-F. Chen, A. Avery, K. Neil, C. Johnson, M. Dewey, and I. Stockly. Incidence and possible causes of prescribing potential hazardous/contraindicated drug combinations in general practice. Drug Safety, 28:67--80, 2005.

[8]

Committee on Identifying and Preventing Medication Errors. Preventing medication errors. Technical report, Institute of Medicine, 2006. 0309102685.

[9]

U. Congress. Code of Federal Regulations 21 Part 201, chapter Labeling. Washington, DC: US Government Printing Office, 2010.

[10]

U. Congress. Code of Federal Regulations 21 Part 201.56, chapter Requirements on content and format of labeling for human prescription drug and biological products. Washington, DC: US Government Printing Office, 2010.

[11]

T. Fayruzov, M. D. Cock, C. Cornelis, and V. Hoste. Linguistic feature analysis for protein interaction extraction. BMC Bioinformatics, 10: 374, 2009. 19909518.

[12]

G.D.-Searle-LLC. COVERA-HS (verapamil hydrochloride) tablet, extended release. FDA-approved drug product labeling, 04 2010. Lastaccessed on Daily Med 05/22/2010.

[13]

Global-Pharmaceuticals. GEMFIBROZIL tablet, coated. FDA-approved drug product labeling, 092009. Last accessed on DailyMed 05/22/2010.

[14]

J. Gurwitz, T. Field, J. Judge, P. Rochon, L. Harrold, C. Cadoret, M. Lee, K. White, J. LaPrino, J. Erramuspe-Mainard, M. DeFlorio, L. Gavendo, J. Auger, and D. Bates. The incidence of adverse drug events in two large academic long-term facilities. Am J Med, 118: 251--258, 2005.

[15]

Internal. FDA guideline: Drug interaction studies - study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101. pdf, Sept. 2006. Last Accessed: 03/31/2010.

[16]

IVAX. cimetidine (Cimetidine) tablet, film coated. FDA-approved drug product labeling, 08 2008. Last accessed on DailyMed 12/28/2009.

[17]

D. N. Juurlink, M. Mamdani, A. Kopp, A. Laupacis, and D. A. Redelmeier. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA, 289(13): 1652--1658, 2003.

[18]

P. Marroum and J. Gobburu. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet., 41(3):161--9, 2002.

[19]

G. Móra, R. Farkas, G. Szarvas, and Z. Molnár. Exploring ways beyond the simple supervised learning approach for biological event extraction. In BioNLP '09: Proceedings of the Workshop on BioNLP, pages 137--140, Morristown, NJ, USA, 2009. Association for Computational Linguistics.

Digital Library

[20]

Mutual. PROPAFENONE HYDROCHLORIDE tablet, film coated. FDA-approved drug product labeling, 07 2009. Last accessed on DailyMed 05/15/2010.

[21]

Mylan. cimetidine (Cimetidine) tablet, film coated. FDA-approved drug product labeling, 07 2007. Last accessed on DailyMed 12/28/2009.

[22]

S. H. Preskorn. How drug-drug interactions can impact managed care. The American Journal of Managed Care, 10(6 Suppl): S186--S198, July 2004.

[23]

Teva. trimethoprim (Trimethoprim) tablet. FDA-approved drug product labeling, 06 2008. Last accessed on DailyMed 05/22/2010.

[24]

Teva Pharmaceuticals. fluconazole (fluconazole) Teva. FDA-approved drug product labeling, 10 2006. Last accessed on DailyMed 05/22/2010.

[25]

Watson. mexiletine hcl (Mexiletine hydrochloride) capsule. FDA-approved drug product labeling, 04 2008. Last accessed on DailyMed 05/22/2010.

[26]

D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res, 34(Database issue): D668--D672, 2006.

[27]

R. Yuan, T. Parmelee, J. D. Balian, R. S. Uppoor, F. Ajayi, A. Burnett, L. J. Lesko, and P. Marroum. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther, 66(1):9--15, 1999.

Cited By

Sharp M(2017)Toward a comprehensive drug ontology: extraction of drug-indication relations from diverse information sourcesJournal of Biomedical Semantics10.1186/s13326-016-0110-08:1Online publication date: 10-Jan-2017
https://doi.org/10.1186/s13326-016-0110-0
Martin-Hammond AGilbert JFavela JWeibel N(2016)Examining the effect of automated health explanations on older adults' attitudes toward medication informationProceedings of the 10th EAI International Conference on Pervasive Computing Technologies for Healthcare10.5555/3021319.3021346(186-193)Online publication date: 16-May-2016
https://dl.acm.org/doi/10.5555/3021319.3021346
Li QDeleger LLingren TZhai HKaiser MStoutenborough LJegga ACohen KSolti I(2013)Mining FDA drug labels for medical conditionsBMC Medical Informatics and Decision Making10.1186/1472-6947-13-5313:1Online publication date: 24-Apr-2013
https://doi.org/10.1186/1472-6947-13-53

Index Terms

Leveraging the semantic web and natural language processing to enhance drug-mechanism knowledge in drug product labels
1. Software and its engineering
  1. Software creation and management
    1. Designing software
      1. Requirements analysis

Recommendations

Drug Repurposing: Targeting mTOR Inhibitors for Anticancer Activity
CSBio '17: Proceedings of the 8th International Conference on Computational Systems-Biology and Bioinformatics

In the search of safer and more effective drugs while reducing costs and increasing productivity of novel drug discovery, scientists are changing their focus to an approach known as drug repurposing. This involves finding a new therapeutic effect of an ...
Potential drug-drug interactions in pediatric outpatient prescriptions for newborns and infants

ObjectivesTo surveyed the quantities, types, and related information of potential drug-drug interactions (DDIs) and estimate the off-label use percentage of pediatric outpatient prescriptions for newborns and infants from the National Health Insurance ...
Physicians' responses to computerized drug-drug interaction alerts for outpatients

IntroductionAdverse drug reactions (ADR) increase morbidity and mortality; potential drug-drug interactions (DDI) increase the probability of ADR. Studies have proven that computerized drug-interaction alert systems (DIAS) might reduce medication errors ...

Comments

Information & Contributors

Information

Published In

cover image ACM Other conferences

IHI '10: Proceedings of the 1st ACM International Health Informatics Symposium

November 2010

886 pages

ISBN:9781450300308

DOI:10.1145/1882992

Editor:
Tiffany Veinot
University of Michigan, USA
,
General Chairs:
Ümit V. Çatalyürek
The Ohio State University, USA
,
Gang Luo
IBM Research, USA
,
Program Chairs:
Henrique Andrade
Goldman Sachs, USA
,
Neil R. Smalheiser
University of Illinois, Chicago, USA

Copyright © 2010 ACM.

Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]

In-Cooperation

SIGHIT: ACM Special Interest Group on Health Informatics

Publisher

Association for Computing Machinery

New York, NY, United States

Publication History

Published: 11 November 2010

Permissions

Request permissions for this article.

Request Permissions

Check for updates

Author Tags

Qualifiers

Poster

Conference

IHI '10

IHI '10: ACM International Health Informatics Symposium

November 11 - 12, 2010

Virginia, Arlington, USA

Contributors

Other Metrics

View Article Metrics

Bibliometrics & Citations

Bibliometrics

Article Metrics

3
Total Citations
View Citations
240
Total Downloads

Downloads (Last 12 months)0
Downloads (Last 6 weeks)0

Reflects downloads up to 13 Jan 2025

Other Metrics

View Author Metrics

Citations

Cited By

Sharp M(2017)Toward a comprehensive drug ontology: extraction of drug-indication relations from diverse information sourcesJournal of Biomedical Semantics10.1186/s13326-016-0110-08:1Online publication date: 10-Jan-2017
https://doi.org/10.1186/s13326-016-0110-0
Martin-Hammond AGilbert JFavela JWeibel N(2016)Examining the effect of automated health explanations on older adults' attitudes toward medication informationProceedings of the 10th EAI International Conference on Pervasive Computing Technologies for Healthcare10.5555/3021319.3021346(186-193)Online publication date: 16-May-2016
https://dl.acm.org/doi/10.5555/3021319.3021346
Li QDeleger LLingren TZhai HKaiser MStoutenborough LJegga ACohen KSolti I(2013)Mining FDA drug labels for medical conditionsBMC Medical Informatics and Decision Making10.1186/1472-6947-13-5313:1Online publication date: 24-Apr-2013
https://doi.org/10.1186/1472-6947-13-53

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Full Access

Get this Publication

View options

PDF

View or Download as a PDF file.

eReader

View online with eReader.

Media

Figures

Other

Tables

View Table of Contents